of high bleeding risk patients post bioresorbable polymer coated
with an abbReviated
versus standard DAPT
Featured product: Ultimaster™ Tansei™ Sirolimus Eluting Coronary Stent System
About MASTER DAPT Study
MASTER DAPT is the largest multi-center
randomized controlled study on the use of short duration of dual
antiplatelet therapy (DAPT) in high bleeding risk patients following
stenting procedures with Ultimaster™/Ultimaster™TanseiTM
drug-eluting bioresorbable polymer stents (DES).
MASTER DAPT study is sponsored by the
European Cardiovascular Research Institute (ECRI, Rotterdam, The
Netherlands) and supported with a restricted research grant by Terumo
Europe. The study is managed by global CROs and data management group
(CERC, Paris, France, Cardialysis, Rotterdam, The Netherlands, CV
quest. Co. Ltd., Tokyo, Japan and CTU, Bern, Switzerland).
MASTER DAPT Study Highlights
MASTER DAPT Study Design - A true
randomized DAPT study
MASTER DAPT has met the three
DAPT after implantation of Ultimaster™
family DES does not
increase the ischemic risk, but
reduces the bleeding risk in
high bleeding risk patients
with acute coronary syndrome, and patients who underwent complex
or multivessel PCI were included
reduction of DAPT duration to 1 month after
implantation of Ultimaster™ family
DES in a broad cohort of
high-bleeding risk patients
included patients at high bleeding risk who had undergone
implantation of Ultimaster™ family stent; Results may not
extend to patients who are not at high bleeding risk or who receive
other stent types.
non-inferior to standard DAPT in terms of NACE
adverse clinical events (NACE, a composite of death from any cause,
myocardial infarction, stroke, or major bleeding)*
non-inferior to standard DAPT in terms of MACCE
cardiac and cerebral events* (MACCE, a composite of death from any
cause, myocardial infarction, or stroke)
superior to standard DAPT in terms of bleeding
Major or clinically relevant non-major
Publications on MASTER DAPT
DualAntiplatelet Therapy after PCI in Patients at High Bleeding Risk.
Marco Valgimigli, M.D., Ph.D et al. The New England Journal of
Medicine, August 28, 2021, DOI: 10.1056/NEJMoa2108749
Antiplatelet Therapy in Patients at High Bleeding Risk With or
Without Oral Anticoagulant Therapy After Coronary Stenting: An
Open-Label, Randomized, Controlled Trial. Pieter C. Smits et al.
Circulation, August 29, 2021, 10.1161/CIRCULATIONAHA.121.056680
The UltimasterTM clinical program included more than 50,000 patients covering 16 CE-marked indications. Learn more
This is HCP only content
website and cannot be refused. Other cookies are only placed if you choose to do so. For further information, please read our cookies policy.
Essential cookies to ensure the website functions well.
Cookies to help us measure the general use of our website.
Cookies that save personal information while browsing.